Copyright © All rights reserved | Ariel Munitz Lab

aAriel Munitz, אריאל מוניץ

Publications

Peer-reviewed papers
  1. Reichman H, Itan M, Rozenberg P, Yarmolovski T, Brazowski E, Varol C, Gluck N, Shapira S, Arber N, Qimron U, Karo-Atar D, Lee JJ, Munitz A. Activated eosinophils exert distinct anti-tumorigenic activities in colorectal cancer. Cancer Immunol Res. 2019;7:388-400. PDF

  2. Shlomovitz I, Erlich Z, Speir M, Zargarian S, Baram N, Edry-Botzer L, Munitz A, Croker BA, Gerlic M. Necroptosis directly induces the release of full-length biologically active IL-33 in vitro and in an inflammatory disease model. FEBS. 2018; In Press.  PDF

  3. Lee EH, Itan M, Jang J, Gu HJ, Rozenberg P, Mingler MK, Wen T, Yoon J, Park SY, Roh JY, Choi CS, Park WJ, Munitz A, Jung Y. Eosinophils support adipocyte maturation and promote glucose tolerance in obesity. Sci Rep. 2018;8:9894. doi: 10.1038/s41598-018-28371-4.  PDF

  4. Grace JO, Malik M, Reichman H, Munitz A, Barski A, Fulkerson PC. Reuse of public, genome-wide, murine eosinophil expression data for hypotheses development. J Leuk Biol. 2018: 2018: doi: 10.1002/JLB.1MA1117-444R.  PDF

  5. Salamon P, Shefler I, Moshkovits I, Munitz A, Klotzman HK, Mekori Y, Hershko A. IL-33 and IgE stimulate mast cell production of IL-2 and regulatory T cell expansion in allergic dermatitis. Clin Exp Allergy. 2017: 47; 1409-1416.  PDF

  6. Reichman H, Moshkovits I, Itan M, Pasmanik-Chor M, Vogl T, Roth J, Munitz A. Transcriptome profiling of mouse colonic eosinophils reveals a key role for eosinophils in the induction of s100a8 and s100a9 in mucosal healing. Sci Reports. 2017; 7:7117. doi: 10.1038/s41598-017-07738-z.  PDF

  7. Rozenberg P, Reichman H, Zab-Bar I, Itan M, Pasmanik-Chor M, Bouffi C, Qimron U, Bachelet I, Fulkerson PC, Rothenberg ME, Munitz A. CD300f:IL-5 cross-talk inhibits adipose tissue eosinophil homing and subsequent IL-4 production. Sci Reports. 2017; 7:5922. doi: 10.1038/s41598-017-06397-4.  PDF

  8. Amit U, Kain D, Wagner A, Sahu A, Nevo-Caspi Y, Gonen N, Molotski N, Konfino T, Landa N, Naftali-Shani N, Blum G, Merquiol E, Karo-Atar D, Kanfi Y, Paret G, Munitz A, Cohen HY, Ruppin E, Hannenhalli S, Leor J. A New Role for Interleukin-13 Receptor α1 in Myocardial Homeostasis and Heart Failure. J Am Heart Ass. 2017: 6(5). pii: e005108. doi: 10.1161/JAHA.116.005108.  PDF

  9. Goldman SF, Moshkovits I, Filiba A, Tsirulsky Y, Shemesh A, Vronov E, Shagan M, Apte RN, Benharroch D, Karo-Atar D, Dagan R, Munitz A, Mizrachi Nebenzahl Y, Porgador A. Natural killer receptor 1 dampens the development of allergic eosinophilic airway inflammation. PLoS One. 2016:11;e0160779 (doi: 10.1371/journal.pone.0160779).  PDF

  10. Moshkovits I, Reichman H, Karo-Atar D, Rozenberg P, Zigmond E, Ziv-Haberman Y, Ben-Baruch-Morgenstern N, Lampinen M, Carlson M, Itan M, Denson LA, Varol C, Munitz A. A key requirement for CD300f in innate immune responses of eosinophils in colitis. Mucosal Immunol. 2017 Jan;10(1):172-183. doi: 10.1038/mi.2016.37.  PDF

  11. Yosef I, Edgar R, Levy A, Sorek R, Munitz A, Qimron U. Natural selection acts alone to give the appearance of "stress-induced" mutagenesis. Nature Microbiol. 2016:1;6047s. (doi: 10.1038/nmicrobiol.2016.47).  PDF

  12. Ben-Baruch-Morgenstern N, Mingler MK, Stucke EM, Besse JA, Wen T, Reichman H, Munitz A*, Rothenberg ME*. Paired immunoglobulin-like receptor B inhibits IL-13–driven eosinophil accumulation and activation in the esophagus. J Immunol. 2016;197:707-14. (*-Equal contribution).  PDF

  13. Caspi M, Firsow A, Rajkumar R, Skalka N, Moshkovitz I, Munitz A, Pasmanik-Chor M, Greif H, Megido D, Kariv R, Rosenberg DW, Rosin-Arbesfeld R. A flow cytometry-based reporter assay identifies macrolide antibiotics as nonsense mutation read-through agents. J Mol Med. 2015 [Epub ahead of print].  PDF

  14. Knipper JA, Willenborg S, Brinckmann J, Bloch W, Maaß T, Wagener R, Krieg T, Sutherland T, Munitz A, Rothenberg ME, Niehoff A, Richardson R, Hammerschmidt M, Allen JE, Eming SA. Interleukin-4 Receptor α Signaling in Myeloid Cells Controls Collagen Fibril Assembly in Skin Repair. Immunity. 2015;43(4):803-16.  PDF

  15. Moshkovits I, Karo-Atar D, Shik D, Reichman H, Itan M, Ejarque-Ortiz A, Hershko AY, Tian L, Coligan JE, Sayos J, Munitz A. CD300f associates with IL-4 receptor a and is required for IL-4-induced cellular responses. Proc Natnl Acad Science USA; 2015:112;8708-13.  PDF

  16. Karo-Atar D, Bordowitz A, Wand O, Pasmanik-Chor M, Fernandez IE, Itan M, Frenkel R, Herbert DR, Eickelberg O, Munitz A. A protective role for IL-13 receptor a 1 in bleomycin-induced pulmonary fibrosis. Mucosal Immunol: 2016 Jan;9(1):240-53. doi: 10.1038/mi.2015.56.  PDF

  17. Karo-Atar D, Itan M, Pasmanik-Chor M, Munitz A. MicroRNA profiling reveals opposing expression patterns for miR-511 in alternatively and classically activated macrophages. J Asthma. 2014: 18:1-25.  PDF

  18. Shik D, Moshkovits I, Karo-Atar D, Reichman H, Munitz A. IL-33 requires CMRF35-like molecule 1 (CLM-1) expression for induction of myeloid cell activation. Allergy. 2014:69;719-29.  PDF

  19. Ben Baruch-Morgenstern N, Shik D, Moshkovits I, Itan M, Karo-Atar D, Bouffi C, Fulkerson PC, Rashkovan D, Jung S, Rothenberg M, Munitz A.  Paired immunoglobulin-like receptor A is an intrinsic, self-limiting pathway suppressing IL-5-induced eosinophil development. Nat Immunol. 2014:36-44.  PDF

  20. Moshkovits I, Shik D, Itan M, Karo-Atar D, Bernshtein B, Hershko AY, van Lookeren Campagne M, Munitz A. CMRF35-like molecule 1 (CLM-1) regulates eosinophil homeostasis by suppressing cellular chemotaxis. Mucosal Immunol; 2014:7;292-303.  PDF

  21. Karo-Atar D, Moshkovits I, Eickelberg O, Königshoff M, Munitz A. PIR-B regulates pulmonary fibrosis by suppressing profibrogenic properties of alveoalar macrophages. Am J Res Cell Mol Biol. 2013; 48:456-464.  PDF

  22. Semis R, Shai N, Munitz, A, Zaslavsky Z, Polacheck I, Segal E. Pharmacokinetics, tissue distribution and immunomodulatory effect of intralipid formulation of nystatin in mice. J of Antimicrob Chem; 2012;67:1716-21.  PDF

  23. Munitz A, Cole ET, Karo-Atar D, Finkelan FD, Rothenberg ME. Resistin-like molecule alpha regulates IL-13-induced chemokine production but not allergen-induced airway responses. Am J Res Cell Mol Biol; 2012;46:703-13.  PDF

  24. Rothenberg ME, Cole ET, Shik D, Mingler MM, Munitz A. IL-13 receptor 1 differentially regulates aeroallergen induced lung responses. J Immunol; 2011; 187:4873-80.  PDF

  25. Waddell A, Ahrens R, Steinbrecher K, Donovan B, Rothenberg ME, Munitz A, Hogan SP. Colonic eosinophilic inflammation in experimental colitis is mediated by Ly6C(high) CCR2(+) inflammatory monocyte/macrophage-derived CCL11. J Immunol. 2011;186:5993-6003.  PDF

  26. Munitz A, Cole ET, Waddell A, Groschwitz K, Ahrens R, Steinbrecher K, Willson T, Han X, Denson L, Rothenberg ME, Hogan SP. Paired immunoglobulin-like receptor B (PIR-B) negatively regulates macrophage activation in experimental colitis. Gastroenterology. 2010;139:530-41. PDF

  27. Herbert DR, Wang JQ, Hogan SP, Groshwitz K, Khodoun M, Munitz A, Orekov T, Perkins C, Wang Q, Brombacher F, Urban Jr. JF, Rothenberg ME, and Finkelman FD. IL-4 and IL-13 protect against intestinal worms by inducing epithelial cells to secrete RELM-b. J Exp Med. 2009; 206:2947-57.  PDF

  28. Munitz A, Seidu L, Ahrens R, Cole E, Hogan SP, Rothenberg ME. Resistin-like molecule a decreases glucose tolerance during intestinal inflammation. J Immunol. 2009;182:2357-63.  PDF

  29. Lu TX, Munitz A, Rothenberg ME. MicroRNA-21 is up-regulated in allergic airway inflammation and regulates IL-12p35 expression. J Immunol. 2009;182:4994-5002.  PDF

  30. Takeda A, Baffi JZ, Kleinman ME, Cho WG, Nozaki M, Yamada K, Kaneko H, Albuquerque RJ, Dridi S, Saito K, Raisler BJ, Budd SJ, Geisen P, Munitz A, Ambati BK, Green MG, Ishibashi T, Wright JD, Humbles AA, Gerard CJ, Ogura Y, Pan Y, Smith JR, Grisanti S, Hartnett ME, Rothenberg ME, Ambati J. CCR3 is a target for age-related macular degeneration diagnosis and therapy. Nature. 2009;460:225-30.  PDF

  31. Nissim Ben Efraim AH, Munitz A, Sherman Y, Mazer BD, Levi-Schaffer F, Eliashar R. Efficient purification of eosinophils from human tissues: A comparative study. J Immunol Methods. 2009;343:91-6. PDF

  32. Munitz A, Beichler A, Seidu L, Ahrens R, Cole E, Hogan SP, Rothenberg ME. Resistin-like molecule a enhances myeloid cell activation and promotes colitis. J Allergy Clin Immunol. 2008;122:1200-1207.  PDF

  33. Munitz A, McBride ML, Bernstein JB, Rothenberg ME. A dual activation and inhibition role for the paired immunoglobulin-like receptor B (PIR-B) in eosinophils. Blood. 2008;111(12):5694-703.  PDF

  34. Munitz A, Brandt EB, Mingler M, Finkelmen FD, Rothenberg ME. Distinct roles for IL-13 and IL-4 via IL-13 receptor alpha 1 and the type II IL-4 receptor in asthma pathogenesis. Proc Natl Acad Sci U S A. 2008 105:7240-5.  PDF

  35. Ahrens R, Beichler A, Seidu L, Blanchard C, Carey  R, Forbes E, Wilson T,  Cohen E, Ballard E, Munitz A, Lee N, Lee JJ, Rothenberg ME, Denson L, Hogan SP. Macrophage/Intestinal epithelial cell-derived CCL11/eotaxin-1 mediates eosinophil recruitment and function in Pediatric Ulcerative Colitis. J Immunol. 2008;181:7390-9.  PDF

  36. Brandt EB, Munitz A, Orekov T, Mingler MK, McBride M, Finkelman FD, Rothenberg ME. Targeting IL-4/IL-13 signaling to alleviate oral allergen-induced diarrhea. J Allergy Clin Immunol. 2008;122:1200-1207.  PDF

  37. Bachelet I, Munitz A, Berent-Maoz B, Mankuta D, Levi-Schaffer F. Suppression of normal and malignant kit signaling by a bispecific antibody linking kit with CD300a. J Immunol. 2008. 180:6064-9.  PDF

  38. Munitz A, Bachelet I, Finkelman FD, Rothenberg ME, Levi-Schaffer F. CD48 is critically involved in allergic eosinophilic airway inflammation. Am J Respir Crit Care Med. 2007;175:911-8.  PDF

  39. Munitz A, Bachelet I, Moretta A, Moretta L, Levi-Schaffer F. The Inhibitory receptor IRp60 suppresses the effects of eotaxin and IL-5/GM-CSF on human eosinophils. Blood. 2006; 107:1996-2003.  PDF

  40. Munitz A, Bachelet I, Eliashar R, Khodoun M, Finkelman FD, Rothenberg ME, Levi-Schaffer F. CD48 is an allergen and IL-3-induced activation molecule on eosinophils. J Immunol. 2006;177:77-83.  PDF

  41. Bachelet I, Munitz A, Mankuta D, Levi-Schaffer F. Mast cell costimulation by CD226/CD112 (DNAM-1/Nectin-2): a novel interface in the allergic process. J Biol Chem. 2006;281(37):27190-6.  PDF

  42. Munitz A, Bachelet I, Levi-Schaffer F. Reversal of airway inflammation and remodeling in asthma by a bispecific antibody fragment linking CCR3 to CD300a. J Allergy Clin Immunol. 2006;118:1082-9.  PDF

  43. Bachelet I*, Munitz A*, Levi-Schaffer F. Abrogation of allergic reactions by a bispecific antibody fragment linking IgE to CD300a. J Allergy Clin Immunol. 2006;117(6):1314-20.  PDF

  44. Bachelet I*, Munitz A*, Moretta A, Moretta L, Levi-Schaffer F. The Inhibitory receptor IRp60 is expressed and functional on human mast cells. J Immunol. 2005;175:12:7989-95.  PDF

  45. Munitz A, Bachelet I, Fraenkel S, Katz G, Mandelboim O, Simon Hans Uwe, Moretta Lorenzo, Colonna Marco, Levi-Schaffer F. 2B4 (CD244) is expressed and functional on human eosinophils. J Immunol. 2005;174:110-8.  PDF
     

Peer-reviewed reviews
  1. Karo-Atar D, Bitton A, Benhar I, Munitz A. Therapeutic Targeting of the Interleukin-4/Interleukin-13 Signaling Pathway: In Allergy and Beyond. BioDrugs. 2018: doi: 10.1007/s40259-018-0280-7. PDF
     

  2. Rozenberg P, Reichman H, Moshkovits I, Munitz A. CD300 family receptors regulate eosinophil survival, chemotaxis and effector functions. J Leuk Biol. 2017:doi:10.1002/JLB.2MR1117-433R. PDF
     

  3. Reichman H, Karo-Atar D, Munitz. A. Eosinophils: “underdogs” of the tumor microenvironment. Trends in Cancer. 2016; 2:664-675. DOI: http://dx.doi.org/10.1016/j.trecan.2016.10.002.  PDF
     

  4. Stein M, Munitz A. Targeting interleukin 5 in asthma and hypereosinophilic syndromes. Recent Pat on Inflamm Allergy Drug Discov. 2010:4;201-9.  PDF
     

  5. Shik D, Munitz A. Inhibitory receptors in activation and suppression of the immune response”. Clin Exp Allergy. 2010:40; 700-709.  PDF
     

  6. Munitz A. Inhibitory receptors on myeloid cells: new targets for therapy? Pharmacol Ther. 2010:125; 128-37.  PDF
     

  7. Munitz A, Levi-Schaffer F. Targeting inhibitory receptors on eosinophils: a direct hit to the Achilles heel. J Allergy Clin Immunol. 2007;119:1382-7.  PDF
     

  8. Bachelet I, Munitz A, Levi-Schaffer F. Tryptase as an inflammatory marker in allergic disease and asthma. Expert Rev Clin Immunol. 2005:1;63-73.  PDF
     

  9. Munitz A, Levi-Schaffer F. Eosinophils: ”new” roles for “old” cells. Allergy. 2003;59:268-275.  PDF
     

Editorials
  1. Munitz A, Hogan SP. Alarming eosinophils to combat cancer. Nat Immunol. 2018; Submitted.  PDF
     

  2. Karo-Atar D, Munitz A. Is Asthma Paying the Toll? Am J Res Cell Mol Biol. 2018;58:3-4. doi: 10.1165/rcmb.2017-0288ED.  PDF
     

  3. Rosenberg HF, Fryer AD, Munitz A, Bochner BS, Jacoby DB, Levi-Schaffer F, Gleich GJ, Furuta GT, Rothenberg ME, Lacy P, Fulkerson PC, Hogan SP, Ackerman SJ, Foster PS. In Memory and Celebration: Dr. James J. Lee. Clin Exp Allergy. 2017 May 26. doi: 10.1111/cea.1295.  PDF
     

  4. Reichman H, Munitz A. Research Highlight: Harnessing Class II Histone Deacetylases in Macrophages to Combat Breast Cancer. Cell Mol Immunol. 2017:14:575-577. doi: 10.1038/cmi.2017.32.  PDF
     

  5. Munitz A, Karo-Atar D, Foster PS. Asthma Diagnosis: miRNA’s to the rescue. J Allergy Clin Immunol. 2016.  PDF
     

  6. Munitz A, Foster PS. Th9 cells: Above and beyond Th2. J Allergy Clin Immunol. 2012;129:1011-3.  PDF
     

  7. Lacy P, Munitz A. Mutations in CCR3 render it “missing in action”. J Allergy Clin Immunol. 2010: 126:158-9.  PDF
     

Book chapters
  1. Reichman H. Rozenberg P. Munitz A. “The identification, isolation and analysis of function for mouse eosinophils”. In Current Protocols in Immunology (Wiley, ed. Coligan JE), 2017;119:14.43.1-14.43.22. doi: 10.1002/cpim.35.  PDF
     

  2. Munitz A. Eosinophil Receptor-Mediated Inhibition. In Eosinophils in health and in disease. (Elsevier, ed. Lee JJ and Rosenberg HF), 2013; pp. 179-188).  PDF
     

  3. Bachelet I, Munitz A, Levi-Schaffer F. Co-culture of mast cells and fibroblasts: a tool to study their cross-talk, Methods Mol Biol. 2006:315;295-317.
     

Patents

1. Munitz, A., Levi-Schaffer F., Bachelet, I., Moretta, L. and Moretta, A. Bi-specific complexes for targeting cells involved in allergic-type reactions, compositions and uses thereof. International Application No. PCT/IL2005/000358. Filing Date: March 30, 2005.
 

2. Munitz A., Levi-Schaffer F., Rothenberg M.E., Bachelet I. CD48 as a novel target for anti-asthmatic and anti-allergic therapy and as a marker for early prediction of allergy. US Provisional Patent Application No. 60/772,883. Filing Date: February 14, 2006
 

3. Munitz A, Bachelet I, Abu-Horwits A, Ben-Ishay E, Amir Y, Zalevsky Z, Shemer A, Shapiro A. DNA origami acid having uniform activity. US Provisional Patent Application No. 61/813,412. Filing Date: April 18, 2013
 

4. Munitz A, Benhar I, Karo-Atar D, Bitton A. Targeting IL-13 receptor alpha 1 in allergic and fibrotic diseases. US Provisional Patent Application 62/330,276.